Inflammasome Lab research on inflammatory disease treatment attracts $22m global investment
Research from the Inflammasome Lab performed by Dr Rebecca Coll (pictured) and Dr Kate Schroder, in collaboration with Dr Avril Robertson and Professor Matt Cooper (Institute for Molecular Bioscience, The University of Queensland), and Professor Luke O’Neill's team (Trinity College Dublin, UK), has attracted investment for a new start-up company to develop treatments for inflammatory disorders including Parkinson’s disease and asthma.
The €15 million (A$22 million) investment, co-led by two top global life science investment firms, Novartis Venture Fund and Fountain Healthcare Partners, is one of the largest biotech Series A investments for intellectual property originating from an Australian university.
Copyright © 2017 - The University of Queensland